基于Car-T细胞疗法在治疗血液恶性肿瘤方面取得的令人瞩目的成功，实体瘤的广泛应用似乎也充满希望。然而，一些重要的障碍需要克服。其中之一当然是癌细胞上特定靶抗原的识别。低甲基化是许多肿瘤实体的特征性表观遗传畸变。对肿瘤中一致的 DNA 低甲基化进行全基因组筛查，能够识别异常上调的转录本，这可能会导致细胞表面蛋白的产生。因此，这种方法为发现几乎所有肿瘤实体的潜在新 Car-T 细胞靶抗原提供了新的视角。首先，我们重点关注这种方法作为前列腺癌的可能治疗方法。

Based on the impressive success of Car-T-cell therapy in the treatment of hematological malignancies, a broad application for solid tumors also appears promising. However, some important hurdles need to be overcome. One of these is certainly the identification of specific target antigens on cancer cells. Hypomethylation is a characteristic epigenetic aberration in many tumor entities. Genome-wide screenings for consistent DNA hypomethylations in tumors enable the identification of aberrantly upregulated transcripts, which might result in cell surface proteins. Thus, this approach provides a new perspective for the discovery of potential new Car-T-cell target antigens for almost every tumor entity. First, we focus on this approach as a possible treatment for prostate cancer.